Literature DB >> 17105814

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.

Raffaele Landolfi1, Leonardo Di Gennaro, Tiziano Barbui, Valerio De Stefano, Guido Finazzi, Rosamaria Marfisi, Gianni Tognoni, Roberto Marchioli.   

Abstract

In polycythemia vera, vascular risk assessment is based on age and thrombotic history, while the role of other potential predictors of this risk is still uncertain. Thus, we exploited the large database collected by the observational study of the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) to investigate the association of hematologic variables and cardiovascular risk factors with the thrombotic risk. Among 1638 polycythemic patients followed for 2.7 +/- 1.3 years, there were 205 thromboses. Subjects with hypertension had a mild nonsignificant increase in the risk of arterial thrombosis, while this risk was significantly increased by smoking (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.15-3.14; P = .012). The time-dependent analysis adjusted for potential confounders showed that patients with a white blood cell count above 15 x 10(9)/L, compared with those with a white blood cell count below 10 x 10(9)/L, had a significant increase in the risk of thrombosis (HR, 1.71; 95% CI, 1.10-2.65; P = .017), mainly deriving from an increased risk of myocardial infarction (HR, 2.84; 95% CI, 1.25-6.46; P = .013). Thus, leukocyte count may help in defining the vascular risk of polycythemic subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105814     DOI: 10.1182/blood-2006-08-042515

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  102 in total

Review 1.  Future therapies for the myeloproliferative neoplasms.

Authors:  Robyn Scherber; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

2.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

Review 3.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 4.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

5.  Pathophysiology of thrombosis in myeloproliferative neoplasms.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

6.  Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.

Authors:  Keita Kirito; Kenshi Suzuki; Koichi Miyamura; Masahiro Takeuchi; Hiroshi Handa; Shinichiro Okamoto; Brian Gadbaw; Kyosuke Yamauchi; Taro Amagasaki; Kazuo Ito; Masayuki Hino
Journal:  Int J Hematol       Date:  2017-09-27       Impact factor: 2.490

7.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

8.  Neutralize the neutrophils! Neutrophil β1/β2 integrin activation contributes to JAK2-V617F-driven thrombosis.

Authors:  Stephen T Oh
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

9.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

10.  Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.

Authors:  Mihir Raval; Anu Paul
Journal:  Case Rep Neurol       Date:  2010-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.